Bone metabolism

Osteoprotegerin

Serum, plasma (EDTA, Citrate, Heparin), cell culture, synovial fluid

No activity loss for 8 hours at room temperature or up to 2 weeks at 4 °C. Store samples at -20 °C for longer storage. Serum is stable up to 3 freeze and thaw cycles, Heparin only stable for 1 freeze and thaw cycle. Before use, thaw samples at low temperature and mix them thoroughly. Hemolyzed or lipemic sera may cause erroneous results.

Average 5.7 ± 0.42 pmol/l

Human, baboon, rhesus macaque

Osteoprotegerin (OPG) is a secretory glycoprotein belonging to the TNF receptor super family. OPG inhibits the binding of RANK to RANKL and thus inhibits the recruitment, proliferation and activation of osteoclasts. Since OPG exhibits an inhibitory effect on osteoclasts activation, it acts as a soluble factor in the regulation of bone mass. Changes in the homeostasis of the RANKL/RANK/OPG systems causes disturbances in bone remodeling shown by bone damages in patients with postmenopausal osteoporosis, Paget’s disease, bone loss due to cancer metastases and rheumatoid arthritis. Intended applications:

• Postmenopausal and senile osteoporosis
• Glucocorticoid dependent osteoporosis
• Diseases with locally increased resorption activity
• Therapy control of OPG treatments
• Arthritis
• Bone metastases
• Vascular calcification
• Renal cell carcinoma